Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

La Trobe University

  • Home
  •  
  • La Trobe University



  • Most Read
  • Latest Comments
  • Algorae debuts new name with AI modelling partnership with the UNSW
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Algorae debuts new name with AI modelling partnership with the UNSW
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Algorae debuts new name with AI modelling partnership with the UNSW
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Algorae debuts new name with AI modelling partnership with the UNSW
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Algorae debuts new name with AI modelling partnership with the UNSW
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • How Algorae is using AI and supercomputers to transform medicine
    How Algorae is using AI and supercomputers to transform medicine
    • News

  • Algorae teams up with HL Pharma to supply cannaboids for research projects
    Algorae teams up with HL Pharma to supply cannaboids for research projects
    • News

  • Algorae Pharmaceuticals collaborates with UNSW for AI biopharmaceutical prediction platform for dementia and heart diseases
    Algorae Pharmaceuticals collaborates with UNSW for AI biopharmaceutical prediction platform for dementia and heart diseases
    • News

  • Noxopharm’s pancreatic cancer treatment drug slows tumour growth in mice, study shows
    Noxopharm’s pancreatic cancer treatment drug slows tumour growth in mice, study shows
    • News

  • Algorae debuts new name with AI modelling partnership with the UNSW
    Algorae debuts new name with AI modelling partnership with the UNSW
    • News

  • Algorae debuts new name with AI modelling partnership with the UNSW
    • News

    Algorae debuts new name with AI modelling partnership with the UNSW

    In a promising new chapter, Algorae Pharmaceuticals (ASX: 1AI), formerly known as Living Cell Technologies (ASX: LCT), has debuted its new name in a Memorandum of Understanding (MoU) with the University of New South Wales (UNSW).  The MoU outlines a framework for a Master Services Research Agreement (MSRA) between both parties to develop an Artificial

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.